Publications by authors named "How Ting Ong"
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Yao Neng Teo Adriel Z H Ting Yao Hao Teo Elliot Yeung Chong Joshua Teik Ann Tan How Ting Ong Alex Jia Yang Cheong Kian Keong Poh Tiong Cheng Yeo Raymond C C Wong
Am J Cardiovasc Drugs
May 2022
Article Synopsis
- * A thorough search of clinical trial databases revealed 111 studies with over 103,000 patients, focusing on differences in outcomes for type 1 and type 2 diabetes.
- * Results indicated that while SGLT1/2 inhibitors reduced the risk of heart attack and stroke in type 2 diabetes patients, SGLT2 inhibitors were more effective at lowering HbA1c levels; however, SGLT1/2 inhibitors had a higher risk of
Article Synopsis
- A meta-analysis was conducted to evaluate the weight loss effects of SGLT2 inhibitors and the combined SGLT1/SGLT2 inhibitors, using data from various trials published over two decades.
- The analysis included 116 randomized-controlled trials with nearly 100,000 patients, revealing an average weight loss of -1.79 kg and a BMI change of -0.71 kg/m compared to placebo.
- The study found that SGLT1/SGLT2 inhibitors were more effective for weight reduction than SGLT2 inhibitors alone, highlighting their potential in weight management, though more research is needed.
Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis.
How Ting Ong Yao Hao Teo Yao Neng Teo Nicholas Lx Syn Caitlin Fern Wee Shariel Leong Alex Jia Yang Cheong Benjamin Yong-Qiang Tan Leonard Leong-Litt Yeo Tiong-Cheng Yeo Raymond Cc Wong
J Stroke Cerebrovasc Dis
January 2022
Objectives: Recent clinical trials have shown the potential of sodium glucose cotransporter (SGLT) 2 inhibitors to reduce the risk of atrial fibrillation but not stroke. We conducted a systematic review and meta-analysis to clarify if SGLT2 or combined SGLT1/2 inhibitors affect the risk of atrial fibrillation and stroke in patients regardless of diabetic status.
Materials And Methods: Four electronic databases were searched on 21st November 2020 for studies evaluating outcomes of stroke and atrial fibrillation with SGLT2 or combined SGLT1/2 inhibitors in both diabetic and non-diabetic patients.